Recall: D-0508-2026

Class II - Potentially Harmful

Class IIClassification

2026-04-01Initiated

OngoingStatus

Wells Pharma of Houston LLCFirm

Product

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.

Reason

cGMP deviations.

Distribution

U.S. Nationwide.

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.